Aggressiveness has a high prevalence in psychiatric patients and is a major health problem. Two brain areas involved in the neural network of aggressive behavior are the amygdala and the hypothalamus. While pharmacological treatments are effective in most patients, some do not properly respond to conventional therapies and are considered medically refractory. In this population, surgical procedures (ie, stereotactic lesions and deep brain stimulation) have been performed in an attempt to improve symptomatology and quality of life. Clinical results obtained after surgery are difficult to interpret, and the mechanisms responsible for postoperative reductions in aggressive behavior are unknown. We review the rationale and neurobiological characteristics that may help to explain why functional neurosurgery has been proposed to control aggressive behavior. www.neurosurgery-online.com A ggressive behavior is a primitive social conduct that is essential for individuals to compete for food, territory, and mating. In this regard, one may say that it is crucial for the maintenance of the species. 1 In the case of humans, the presence of complex emotions makes understanding the neurobiological mechanisms underlying human aggressive behavior a challenging task. 2, 3 Violent crimes are often committed, and the costs required to address the consequences of these acts are high. Victims require physical and emotional care, and offenders are incarcerated and consequently became a burden on the government as a result of their loss of productivity. 4 One strategy used to study human aggression is to simplify the behavior in a dichotomy model including premeditated (proactive or cold aggression) and impulsive (reactive or hot-headed aggression) aggression. Premeditated aggression involves a planned behavior that is intended to achieve a specific goal and is not ABBREVIATIONS: 5-HT, serotonin; ASD, autism spectrum disorder; DA, dopamine; DBS, deep brain stimulation; GABA, gamma-aminobutyric acid; HFS, high-frequency stimulation; MRI, magnetic resonance imaging; PAG, periaqueductal gray; PTSD, posttraumatic stress disorder; VMH, ventromedial hypothalamic nucleus accompanied by autonomic arousal or anger. Impulsive aggression is unrelated to a specific goal and usually involves frustration, provocation, or stress; this type of aggression is associated with high levels of autonomic arousal and impulsivity. 3 Impulsive aggression is the core symptom of intermittent explosive disorder and presents as a feature of several psychiatric disorders, including schizophrenia, personality disorders (in particular, borderline and antisocial personality disorders), autism spectrum disorder (ASD), posttraumatic stress disorder (PTSD), and bipolar disorder. [4] [5] [6] [7] [8] In addition, aggression in psychiatric patients is frequently associated with other comorbidities, such as anxiety, mood disorders, and sleep disturbances, as described in ASD patients. 6 The association between mental disorders and violent behavior is a common reason for patient institutionalization. 2 Studies in humans and other mammals indicate that the amygdala is a key component of a broader neural circuit that modulates aggressive behavior and also includes the hypothalamus, hippocampus, orbitofrontal cortex, and periaqueductal gray (PAG) matter. 9, 10 The amygdala presents reciprocal connections with the hypothalamus (mainly through the fornix and stria terminalis) and with the PAG (through the ventral amygdalofugal pathway), and receives massive projections from the prefrontal cortex through the uncinate fasciculus. [11] [12] [13] [14] The hypothalamus projects to the PAG via the dorsal longitudinal fasciculus and receives projections from the prefrontal cortex through the medial forebrain bundle. 12, 15, 16 It is believed that impulsive forms of aggressive behavior occur when there is a hyperactivation of the limbic system, with insufficient top-down control from the prefrontal cortex.
3 Figure 1 shows a schematic representation of the main neurocircuitry underlying aggressive behavior.
The dysregulation of the serotonin (5-HT), dopamine (DA), and norepinephrine systems has been implicated in the overexpression of aggression. The impairment of receptor subunits and other neuronal elements, including the serotonin transporter (5-HT transporter), 5-HT1B receptor, gamma-aminobutyric acid A and B (GABA-A and GABA-B) receptors, glutamate (N-methyl D-aspartate) receptor, monoamine oxidase A, nitric oxide synthase, and neuroactive steroids, has been reported in aggressive subjects. [17] [18] [19] It is necessary to integrate and understand these complex neurochemical interactions to effectively treat an aggressive patient. 2 The primary treatment for aggressive behavior involves the use of medications and/or nonpharmacological treatments. 20, 21 Nonpharmacological treatments such as cognitive behavioral therapy and applied behavior analysis have an overall intervention effect that is considered low to medium and are sometimes ineffective. 21, 22 Electroconvulsive therapy is more efficacious but is associated with side effects. 23, 24 As impulsive aggression is often a symptom of associated disorders, first-line treatments are initially chosen to address the primary underlying conditions. 25 As shown in Table 1 , pharmacological treatment of aggressive behavior may involve the use of different classes of medications, such as typical and atypical antipsychotics, antidepressants, benzodiazepines, alpha 2 agonists, mood stabilizers, and anticonvulsants. 6, Typical antipsychotics include dopaminergic antagonists and are effective in treating psychotic patients, children with conduct disorders, and cognitively impaired individuals. 27 Atypical antipsychotics, particularly risperidone and aripiprazole, act on multiple neurotransmitter systems (eg, antagonists of the DA and 5-HT2A receptors) and are effective in the patient populations described above. 27 Their effectiveness is particularly notable in ASD patients for which they are FDA approved. 6, 29 Antidepressants, primarily selective serotonin reuptake inhibitors, are effective in reducing irritability and aggressive behavior in patients with unipolar depression, Alzheimer's disease, autism, mental retardation, psychosis, PTSD, and personality disorders. 32 Mood stabilizers, such as lithium, have been shown to be effective in individuals with intellectual disabilities and physical handicaps, children with conduct-disordered and explosive behavior, and bipolar patients with excessive irritability and outbursts of rage. 31, 50 When patients fail to respond to an adequate dose and duration of a standard monotherapy, a high-dose monotherapy or a polypharmacy strategy may be used. 20, 27 These include the use of typical antipsychotics (2 or more), atypical antipsychotics (2 or more), or a combination of both classes of drugs. However, this type of polypharmacy can increase the burden of side effects, including sedation, akathisia, and dystonia. 27 Despite the variety of drugs and doses used to treat aggression, there is a subset of individuals who do not respond adequately to medical treatment and are considered to be treatment refractory. 29 For this limited population of nonresponsive impulsive aggressive patients, surgical interventions targeting the amygdala or hypothalamus have been proposed. We review the rationale behind and neurobiological mechanisms underlying these interventions and discuss some of the reported outcomes.
A review search was conducted in PubMed, Medline, and Scopus for original research articles. As this study aims to review a great number of published articles on the theme, there were no restrictions placed on the publication date for the search. Thus, we opted not to conduct a formal systematic review or meta-analysis. The studies were required to meet the terms "amygdalotomy," "amygdala," "hypothalamotomy," "hypothalamus," "lesion," "aggressive behavior," "aggression," "deep brain stimulation, " "DBS." The selection criteria included studies that (1) were performed in humans, (2) performed amygdalotomy or hypothalamotomy, (3) were focused on aggressive behavioral disorders. Only English language articles were considered. Studies of all sample sizes were included in the analysis. Studies were excluded if they (1) were reviews of the literature and (2) present repeated data from previous included studies. Figure 2 shows a PRISMA flow diagram describing the study selection performed in Tables 2 and 3 . In order to evaluate the risk of bias/quality assessment of an individual study, the quality was assessed based on Cochrane risk-of-bias tool (see Table 4 ).
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AMYGDALA
The amygdala is an almond-shaped structure located bilaterally in the temporal lobes. Its average size in humans ranges from 1.24 to 1.63 cm 3 . 52 The amygdala plays a critical role in processing threatening stimuli and mediating autonomic, neuroendocrine, and behavioral responses that enable an organism to adapt to social and environmental challenges. 14, 52, 53 In 1923, J. B. Johnston introduced a fundamental description of the amygdala based on a detailed analysis of comparative vertebrate species. 54 He proposed subdividing the structure into a primitive group of nuclei associated with the olfactory system (the central, medial, and cortical nuclei and the nucleus of the lateral olfactory tract) and a phylogenetically newer group (the lateral and basal nuclei). More recently, a greater heterogeneity of regions within the amygdala has been unraveled, with one portion viewed as a ventromedial extension of the striatum, a second part comprising the caudal olfactory cortex, and a third region representing the ventromedial extension of the claustrum. 53, 55 Furthermore, the amygdala has been subdivided based on its histological characteristics into 2 major areas (anterior amygdaloid area and corticoamygdaloid transition area), 6 nuclei (central, medial, cortical, accessory basal, basal, and lateral), and 1 [47] [48] [49] Increases GABA concentration and/or inhibition of voltage-sensitive sodium channels ADHD, ODD, DB, schizophrenia Low-quality evidence to support the use of this drug ADHD = attention deficit/hyperactivity disorder; ASD = autism spectrum disorder; DB = disruptive behavior; ID = intellectual disability; ODD = oppositional defiant disorder; PTSD = posttraumatic stress disorder.
intercalated cell group. As the subdivision of the human amygdala proposed by Sims and Williams presents good homology with experimental animals, it will be used in this review. 56 The lateral nucleus is viewed as the gatekeeper because it receives inputs from sensory systems (ie, visual, auditory, somatosensory, pain, olfactory, and taste) and enables the concurrent processing of multiple types of information. 53, 55 The central nucleus is considered a prominent output region for the expression of innate emotional responses and their associated physiological processes, projecting mainly to hypothalamic and brainstem regions. 53 Another important set of output projections from the amygdala arises from the basal nucleus, which directly innervates the central nucleus and striatal areas involved in the control of instrumental behaviors, such as avoidance and escape. 53, 57 A schematic representation of the main projections, inputs, and outputs from the central, basolateral, basomedial, and medial amygdala nuclei is provided in Figure 3 .
Since the beginning of the last century, several studies have been performed with the aim of understanding the role of the amygdala in social and emotional functions. As a result, the amygdala has been considered a key structure in a wide range of conditions from mood disorders to autism and schizophrenia. 58, 59 Likewise, the amygdala is a component of the neural network that regulates aggressive behavior and also includes the hypothalamus, hippocampus, orbitofrontal cortex, and PAG. 3, 10, 17 Studies performed in dogs have shown that the bilateral removal of the temporal lobes has a taming effect. 60 Similarly, bilateral lesions damaging the temporal lobe in nonhuman primates can produce dramatic changes in social and emotional behaviors, including aggressiveness. [61] [62] [63] [64] In a milestone article, Kluver and Bucy 62, 63 demonstrated that bilateral temporal lesions in rhesus monkeys markedly reduced aggressive behavior.
Thereafter, Rosvold and colleagues 64 designed a study to evaluate changes in the social behavior of rhesus monkeys following damage to the amygdala. The researchers established artificial social groups of male rhesus monkeys and identified the dominant animal. A common finding after bilateral lesions of the amygdala was a decrease in social dominance, with the lesioned animals assuming a subordinate position within the group. 64 It is well established that the stimulation or ablation of various amygdalar nuclei in animals produces not only reductions in aggressive behavior but also changes in autonomic functions, such as the heart rate, respiration, and skin conductance. [65] [66] [67] [68] [69] In humans, amygdala stimulation increases aggression. 70 Neuroimaging studies using functional magnetic resonance imaging (MRI) in humans have revealed pronounced amygdala activation when subjects are shown angry or fearful facial expressions. 71, 72 Similar results have been described in patients with antisocial behavior, intermittent explosive disorder, and other psychopathologies, revealing that the amygdala is a core structure Tables 2  and 3 .
involved in the processing of aggressive information, regardless of an individual's psychiatric status. 2, 73 In addition, recent reports have shown that subjective experiences may influence amygdala volume and connectivity. Veterans with aggressive behavior disorders have a more intense brain response to external stimuli, including the amygdala, and have lower connectivity between the amygdala and prefrontal cortex. 74, 75 Similarly, adolescents exposed to family aggression show larger amygdala volume and altered patterns of connections with cortical regions. 74, 76 In contrast, other studies have reported that the level of amygdala activation is lower in criminal psychopaths during processing of negative affective stimuli, fear conditioning paradigms, and emotional moral decision making. [77] [78] [79] These apparently opposite effects could be explained by differences in data processing methods. Some studies have investigated the nucleus as a single compact structure, while others have subdivided it into a few regions. Ablating or stimulating distinct regions within the amygdala may cause different or opposing effects on aggressiveness in both animals and humans. 80, 81 Taken together, these results suggest a relationship between aggressive behavior and amygdala hyperactivity and that the removal of the amygdala may be sufficient to reduce aggressiveness. Although the exact mechanism responsible for the marked reduction in aggressive behavior observed after amygdala lesion remains unknown, it has been suggested that this effect is related to an increase in tolerance to provocation and a decline in the level of autonomic arousal. 82, 83 Taking this into account, investigators proposed the use of amygdalotomy in humans to control extreme aggressive behavior. Table 2 summarizes the published literature on the use of amygdalotomy in humans.
Over the last 60 yr, more than 1000 such surgeries have been reported. Their results have indicated that beneficial effects can be achieved, including reductions in the severity and frequency of aggressive behaviors. [68] [69] [70] [71] [72] [73] As shown in Table 2 , nearly 70% of patients treated with amygdalotomy show good or excellent improvement in behavioral disorders. In patients with concomitant epilepsy, improvements in seizure frequency and intensity have also been reported. There were 6 case reports of only one patient and most studies comprised case series, summing up a total of 1217 patients included in the studies pooled in our review. Although many studies do not reported details of patient psychiatric status, the ones that present this information mostly reports cerebral insults, severe intellectual disabilities, or schizophrenia as cause for the behavioral disturbance. Moreover, several patients had other ablation surgeries performed previously, during or after the amygdalotomy (eg, frontal lobotomy, leucotomy, subcaudate tractotomy, cingulectomy, hypothalamotomy, thalamotomy, fornicotomy, hippocampotomy, fornicotomy, or hypothalamotomy). Thus, a conclusion based on intervention by diagnosis is not possible in those cases.
We note, however, that patients treated with amygdalotomy were often cognitively impaired and nonverbal prior to surgery. Tests to assess other emotional and cognitive aspects (ie, threat processing, avoidance, and approach) 103, 104 were usually not performed. Nevertheless, in most cases, authors reported transient or no postoperative side effects and no impairment in overall measures of intelligence and global memory. However, permanent side effects and worsened behavioral problems have been reported, including movement disorders, depression, and cognitive disturbances involving memory, language, and nonverbal visual stimuli. It is also worth noting that studies published to date have numerous confounders, including differences in age, pathologies underlying the behavioral disturbances, heterogeneity of the behaviors, and most importantly, the use of different surgical ablation procedures before, after, or concomitant to the amygdalotomy. In addition, the methods used to lesion the amygdala, the lateralization of the lesion, and the precise targets that were lesioned varied among surgical centers. Some of the techniques used are now considered obsolete, and modern imaging guidance (eg, highresolution computed tomography, multiplanar 1.5-and 3-Tesla magnetic resonance imaging, and neuronavigational devices) was not available when most of the studies were conducted.
In recent decades, deep brain stimulation (DBS) has emerged as an attractive alternative for treating neurological and psychiatric disorders. [105] [106] [107] [108] This technique involves the insertion of electrodes into specific brain targets and the subsequent local delivery of an electrical current, commonly at high frequencies (HFS; ie, 130-185 Hz). Though DBS and lesions are 2 different therapeutic modalities, common mechanisms of HFS include axonal depolarization and the inhibition of cell bodies in the vicinity of the electrodes. [108] [109] [110] [111] In patients with movement disorders, similar outcomes have been observed with the use of these 2 approaches. 112 The fact that stimulation-induced effects are reversible and adjustable (ie, the current can be reduced or the systems turned off upon the occurrence of side effects) has helped to rekindle interest in the notion that psychiatric diseases can be treated with surgery. 105, 106 In a recent study, DBS was successfully used to treat an autistic teenager with life-threatening selfinjurious behavior refractory to medications. 101 Notwithstanding these promising results of lesions and DBS studies, the vast majority consist of open-label trials in which subjective measures of behavior were used, resulting in a low level of evidence and a high risk of bias, as presented in Table 4 . Ideal surgical targets, the optimal localization within respective nuclei, and the extension/size of the lesions remain to be established. In addition, no detailed information has been provided on postoperative changes in personality and emotions, an issue that will need to be addressed by multidisciplinary teams. Further research is certainly necessary to evaluate the safety of chronic temporal lobe stimulation and to improve our understanding of the mechanisms underlying amygdala DBS.
HYPOTHALAMUS
The hypothalamus is a small diencephalic structure located under the thalamus. It lies on the wall and floor of the third ventricle, extends a few millimeters laterally, and is positioned above the optic chiasm anteriorly and adjacent to the mammillary bodies posteriorly. 113 It is composed of several distinct nuclei with widespread connections throughout the nervous system. 114 The hypothalamus is largely known for its role in controlling homeostasis and motivated behaviors. 114 Based on nuclear landmarks, the hypothalamus can be divided into 3 areas along its rostro-caudal axis: anterior, medial, and posterior. 15 Alternatively, based on the anatomical localization of cells projecting to the pituitary gland, it can be subdivided along its medial-lateral axis into periventricular, medial, and lateral areas. 15, 113, 114 The anterior region is primarily responsible for producing oxytocin and vasopressin and for controlling the circadian cycle; the medial region is associated with producing hypothalamic-releasing hormones and controlling numerous motivated behaviors; and the posterior region is involved in thermoregulation, memory, and emotions.
114,115 Figure 4 shows the main hypothalamic connections based on functions.
Studies performed in animals indicate the presence of specific hypothalamic areas (eg, the ventromedial nucleus of the hypothalamus [VMH] and lateral hypothalamus) that, when electrically stimulated, result in the expression of aggressive behavior. 116, 117 The VMH projects to the anteromedial hypothalamus and the dorsolateral aspect of the PAG. The neurons in the latter region project to other brainstem areas and the spinal cord, and induce autonomic and motor responses when excited. In terms of afferents, the VMH receives massive inputs from the lateral hypothalamus as well as the cortical and basolateral amygdala, which modulate the expression and duration of aggressive behaviors. 118, 119 Similarly, the lateral hypothalamus projects to the midbrain tegmentum, trigeminal motor nucleus, and locus coeruleus, and has reciprocal connections with the PAG. While the latter connections are important for controlling the duration of aggressive episodes, projections from the central, lateral, and basal nuclei of the amygdala facilitate aggressive attacks. 116, 119 In humans, studies suggest that there is a hypothalamic area related to the control of aggressive behavior located in the posteromedial region, an area that includes the midpoint of the anterior commissure/posterior commissure line, the anterior border of the mammillary bodies and the beginning of the aqueduct, and that forms a triangular zone, now called the "Triangle of Sano." 83, 88, 120, 121 Likewise, neuroimaging studies show that the hypothalamus is more activated in individuals with aggressive features and that domestic violence offenders present lower metabolism in this region. 122, 123 Although these results seem conflicting, they reaffirm that the hypothalamus is a component of the neurocircuitry involved in human aggressive behaviors and corroborate the idea that different regions of the hypothalamus are associated with the expression or suppression of these behaviors. 116, 119 Furthermore subthalamic DBS induced acute transient aggressiveness when regions near the hypothalamus were stimulated, 120 suggesting that it may be possible to modulate aggressive behavior by electrically stimulating the hypothalamic region in humans.
In the past century, extremely aggressive patients have been treated with hypothalamic lesions with encouraging results. 83, 88, 121, [124] [125] [126] [127] [128] [129] [130] 131 Table 3 presents the studies using hypothalamic surgery to control aggressive behavior in humans.
When making a hypothalamic lesion, the choice of target is of major importance due to the potential for surgical complications, such as seizures, hyponatremia, cardiovascular changes (including hypertension and tachycardia), disturbances in food and water intake, and thermoregulatory disruption. [132] [133] [134] Transient and permanent side effects have been observed after hypothalamic lesions, with one study reporting a 4% mortality rate. 88, 121 It is important to note that some patients had previous amygdalotomy surgery and patient psychiatric status is not carefully detailed, but overall is similar to that observed in the amygdalotomy studies (eg, severe intellectual disabilities, cerebral insults, and schizophrenia). Nevertheless, in the 243 published cases, the average rate of improvement in aggressive behavior is approximately 80%. This suggests that the hypothalamus may be a very attractive target for modulating aggressive behavior in humans.
Based on these data, DBS hypothalamic surgery has been performed to control aggressive behavior in a few centers around the world. Surgeries have been performed with the aid of modern imaging and surgical planning workstations that merge MRI and stereotactic computed tomography with brain atlases for optimal target localization. DBS studies include patients who suffered cerebral insults, with severe intellectual disabilities, or diagnosed with intermittent explosive disorder, and the average improvement in aggressive behavior after hypothalamic DBS is 91%. Side effects were observed in only a few cases and mainly included headaches that could be easily treated with medication. The most adequate hypothalamic target remains to be determined, as different studies have reported good results following the application of DBS to the posteromedial hypothalamus or the projections from the orbital frontal cortex to the hypothalamus. 100, 135 Even though there are few published reports on this technique, the results so far indicate that long-lasting reductions in violent outbursts, improved control over emotions, and higher quality of life can be achieved following surgery, with minor side effects. Despite these promising results, when viewed from a modern perspective, some studies lacked specific endpoints, specific measuring instruments, and multidisciplinary evaluation. 136 Moreover, the bias analysis shows a high risk of bias for those studies (see Table 4 ) and a low level of evidence; thus, it is not possible to present any formal treatment recommendation. However, this literature undoubtedly has merit and needs to be analyzed according to the time and conditions in which it was published.
SURGICAL PERSPECTIVE
After a promising start, surgery for psychiatric indications was indiscriminately used with poor patient selection and a high incidence of serious side effects, which led to public disbelief. [137] [138] [139] In the 1950s, new pharmacological and nonpharmacological treatments became available, limiting the need for surgical interventions even more. Since its peak, the use of ablative stereotactic surgery for psychiatric disorders has stagnated at a low level and is currently only conducted in a few centers around the world. 140 The reasons for this decrease are multifactorial and include the development of psychopharmacology and the growing skepticism of the international community regarding the benefits of these surgical interventions. 140 Several questions need to be addressed before considering surgery, including indications, patient selection, and criteria for treatment refractoriness. In addition, treating physicians and organizations need to follow regional/federal rules and mandates for conducting psychiatric surgery. If investigational procedures are to be conducted, these should be performed carefully and in a well-documented manner following approval by a research ethics board. The use of psychosurgery should be restricted to extremely severe cases that do not respond to standard/available treatment when no other means of relieving patient suffering is available. [137] [138] [139] 141 To manage the patients, the center is required to have an experienced multidisciplinary team that may provide optimal clinical care and follow-up support. Additionally, such surgeries should be considered as part of a clinical trial in which outcome measures are objective and reproducible. Modern neuroimaging and refined functional neurosurgery techniques are to be used to ensure optimal targeting.
Technically, stereotactic surgery has become widely available, and frameless stereotaxic approaches can now be applied with great precision. 142 Should improvements in targeting translate into ameliorations in surgical outcomes, one may expect a revival of interest in psychiatric surgery, including surgeries used to treat certain cases of medically refractory aggressive behavior. Indeed, ablation in other targets have been previous reported for the control of aggressive behavior (eg, frontal lobotomy, leucotomy, subcaudate tractotomy, cingulectomy, thalamotomy, fornicotomy, hippocampotomy, anterior cingulotomy, anterior capsulotomy) and more recently, nucleus accumbens DBS was performed, with good results. 143 Moreover, patient selfaggressive characteristic and cognitive performance can be a determinant factor when deciding the best surgical technique (ablative/neuromodulatory). More severe patients or those who present aggressive behavior toward face/head may not be eligible for DBS due to a greater risk of complications such as infection, skin erosion, and lead fracture. Thus, future research is certainly necessary for the determination of optimal target and technique.
CONCLUSION
Aggressive behavior is generally managed with medication and/or behavioral approaches. In a small number of well-selected refractory cases, surgery has been proposed with promising results. Due to the potential for side effects, the use of hypothalamotomy and amygdalotomy has been fairly restricted. The reversibility of DBS makes it an attractive alternative for treating these disorders. For all applications of the technique, however, we stress the need for multidisciplinary teams who are experienced in managing aggressive patients. In addition, the treatments must be performed with high ethical standards and in accordance with local legislation.
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